Edition:
United States

Ocular Therapeutix Inc (OCUL.OQ)

OCUL.OQ on NASDAQ Stock Exchange Global Market

5.33USD
14 Dec 2018
Change (% chg)

$-0.31 (-5.50%)
Prev Close
$5.64
Open
$5.64
Day's High
$5.64
Day's Low
$5.29
Volume
93,669
Avg. Vol
105,469
52-wk High
$8.26
52-wk Low
$4.30

Latest Key Developments (Source: Significant Developments)

Ocular Therapeutix Announces FDA Approval Of Dextenza
Monday, 3 Dec 2018 07:00am EST 

Dec 3 (Reuters) - Ocular Therapeutix Inc ::OCULAR THERAPEUTIX™ ANNOUNCES FDA APPROVAL OF DEXTENZA® FOR THE TREATMENT OF OCULAR PAIN FOLLOWING OPHTHALMIC SURGERY.OCULAR THERAPEUTIX INC - INTENDS TO SUBMIT APPLICATION FOR A J-CODE AHEAD OF JANUARY 2019 DEADLINE FOR DEXTENZA.OCULAR THERAPEUTIX - RELATING TO LAUNCH OF DEXTENZA, CO SUBMITTED APPLICATION FOR TRANSITIONAL PASS-THROUGH PAYMENT STATUS AFTER RECEIVING FDA APPROVAL.  Full Article

Ocular Therapeutix Reports Q3 Loss Per Share $0.38
Wednesday, 7 Nov 2018 04:01pm EST 

Nov 7 (Reuters) - Ocular Therapeutix Inc ::OCULAR THERAPEUTIX™ REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE.Q3 LOSS PER SHARE $0.38.Q3 EARNINGS PER SHARE VIEW $-0.38 -- THOMSON REUTERS I/B/E/S.OCULAR THERAPEUTIX - BELIEVES EXISTING CASH, CASH EQUIVALENTS WILL FUND OPERATING EXPENSES, DEBT SERVICE OBLIGATIONS, & CAPEX INTO Q2 2019.AS OF QUARTER ENDED SEPTEMBER 30, 2018, COMPANY HAD $56.9 MILLION IN CASH AND CASH EQUIVALENTS.  Full Article

Ocular Therapeutix Reports Q1 Loss Per Share $0.40
Tuesday, 8 May 2018 04:01pm EDT 

May 8 (Reuters) - Ocular Therapeutix Inc ::OCULAR THERAPEUTIX™ REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE.Q1 LOSS PER SHARE $0.40.Q1 EARNINGS PER SHARE VIEW $-0.38 -- THOMSON REUTERS I/B/E/S.  Full Article

Ocular Therapeutix Reports Q4 Loss Per Share $0.44
Thursday, 8 Mar 2018 07:30am EST 

March 8 (Reuters) - Ocular Therapeutix Inc ::OCULAR THERAPEUTIX™ REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND BUSINESS UPDATE."REAFFIRM GUIDANCE THAT WE ARE ON TRACK FOR A RESUBMISSION OF OUR DEXTENZA NDA IN FIRST HALF OF 2018".QTRLY LOSS PER SHARE $0.44.Q4 EARNINGS PER SHARE VIEW $-0.52 -- THOMSON REUTERS I/B/E/S.  Full Article

Ocular Therapeutix Provides Legal Update
Friday, 22 Dec 2017 04:05pm EST 

Dec 22 (Reuters) - Ocular Therapeutix Inc ::OCULAR THERAPEUTIX™ PROVIDES LEGAL UPDATE.OCULAR THERAPEUTIX INC - ON DEC. 21, CO WAS SERVED WITH A NEW DERIVATIVE COMPLAINT.OCULAR THERAPEUTIX - RECEIVED A SUBPOENA FROM SEC, DATED DEC 15, REQUESTING DOCUMENTS AND INFORMATION CONCERNING DEXTENZA 0.4 MG.  Full Article

Ocular Therapeutix posts Q3 loss per share $0.54
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Ocular Therapeutix Inc :Ocular Therapeutix reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.54.Q3 earnings per share view $-0.53 -- Thomson Reuters I/B/E/S.Ocular Therapeutix Inc - cash and cash equivalents at Sept 30, 2017 $51.2 million versus $32.9 million at Dec 31,2016‍​.Ocular Therapeutix - expects cash, cash equivalents to be enough to fund operating expenses, debt service obligations, capital expenditures into Q4 of 2018​.  Full Article

Ocular Therapeutix Q2 loss per share $0.64
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Ocular Therapeutix Inc :Ocular therapeutix™ reports second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.64.Q2 earnings per share view $-0.56 -- Thomson Reuters I/B/E/S.  Full Article

Ocular Therapeutix to eliminate 26 positions across organization
Tuesday, 1 Aug 2017 05:12pm EDT 

Aug 1 (Reuters) - Ocular Therapeutix Inc ::Ocular Therapeutix says on july 31, board of directors approved a strategic restructuring to eliminate a portion of company's workforce - sec filing.Ocular Therapeutix - company will eliminate 26 positions across organization, representing approximately nineteen percent of company's workforce.Currently expects to substantially complete restructuring and to record restructuring charges in q3 of 2017.Currently anticipates incurring total restructuring costs of approximately $1.5 million.Ocular says co continuing to review potential impact of restructuring; unable to estimate any additional restructuring costs or charges at this time.  Full Article

Ocular Therapeutix receives complete response letter from FDA for Dextenza NDA
Tuesday, 11 Jul 2017 05:00pm EDT 

July 11 (Reuters) - Ocular Therapeutix Inc :Ocular Therapeutix™ receives complete response letter from fda for dextenza™ nda.Ocular Therapeutix inc says outstanding items pertain to form fda-483 close-out of manufacturing deficiencies and analytical testing.Ocular Therapeutix inc says complete response letter states that fda has determined that it cannot approve nda in its present form.Ocular Therapeutix -crl acknowledges receipt of co's nda amendment dated july 10, 2017 and states amendment was not reviewed prior to fda's action of crl.Ocular Therapeutix Inc says as a result, fda did not have opportunity to review company's close-out response prior to issuing crl.Ocular Therapeutix -FDA indicated applicable sections of amendment submitted by ocular could be incorporated when responding to deficiencies noted in crl.Ocular Therapeutix Inc says satisfactory resolution of manufacturing deficiencies detailed in form fda-483 is required before nda may be approved.Ocular Therapeutix -fda's letter did not identify any efficacy or safety concerns with respect to clinical data for dextenza provided in nda.Ocular Therapeutix -fda's letter did not identify any need for additional clinical trials for nda approval.  Full Article

Ocular Therapeutix announces executive transition plans
Thursday, 22 Jun 2017 04:05pm EDT 

June 22 (Reuters) - Ocular Therapeutix Inc -:Ocular Therapeutix announces executive transition plans.Says Antony Mattessich to assume CEO role in September 2017.Says Amar Sawhney to transition to executive chairman of board.Ocular Therapeutix Inc - to facilitate Mattessich's election to board of directors, James Garvey has resigned from board.  Full Article